Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Goethe University Frankfurt · Institute of Clinical Cancer Research · +29 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
734
total citations
- FWCI
- 55.10
- Percentile
- 100%
- References
- 25
Citations per year
Authors
40- SASalah‐Eddin Al‐BatranCorresponding
Goethe University Frankfurt, Institute of Clinical Cancer Research, University Hospital Frankfurt, Krankenhaus Nordwest
- RHRalf‐Dieter Hofheinz
Heidelberg University, University Hospital Heidelberg, University Medical Centre Mannheim
- CPClaudia Pauligk
Goethe University Frankfurt, Institute of Clinical Cancer Research, University Hospital Frankfurt, Krankenhaus Nordwest
- HKHans‐Georg Kopp
University of Tübingen
- GMGeorg Martin Haag
Heidelberg University, University Hospital Heidelberg, National Center for Tumor Diseases
Topics & keywords
Topics
Keywords
- Medicine
- Docetaxel
- Epirubicin
- Capecitabine
- Oxaliplatin
- Fluorouracil
- Internal medicine
- Gastroenterology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.